Роль липидов в патогенезе бокового амиотрофического склероза

Закрыть метаданные

Боковой амиотрофический склероз (БАС) — неизлечимое нейродегенеративное заболевание, характеризующееся селективной дегенерацией двигательных нейронов моторной коры, ствола головного мозга и спинного мозга. Наиболее распространенные представления о причинах данного заболевания заключаются в наличии мутаций в генах белков SOD1, C9ORF72, TDP-43, FUS и др., в нарушении процессинга и транспорта РНК, изменении динамики цитоскелета. Кроме того, обнаружено выраженное изменение метаболизма различных классов липидов, включая фосфолипиды, жирные кислоты, сфинголипиды и др. В обзоре представлены модели БАС животных и данные литературы об изменении содержания липидов и активности ферментов, участвующих в их метаболизме, у модельных животных и пациентов, страдающих данным заболеванием. Наиболее подробно рассмотрены изменения в метаболизме жирных кислот, фосфолипидов, холестерина и его производных. Обсуждаются перспективы поиска новых лекарственных средств среди модуляторов ферментов липидного метаболизма.

Ключевые слова:

боковой амиотрофический склероз (БАС)

Авторы:

Алесенко А.В.

ФГБУН «Институт биохимической физики им. Н.М. Эмануэля» РАН

Гутнер У.А.

ФГБУН «Институт биохимической физики им. Н.М. Эмануэля» РАН

Небогатиков В.О.

ФГБУН «Институт физиологически активных веществ» РАН

Шупик М.А.

ФГБУН «Институт биохимической физики им. Н.М. Эмануэля» РАН

Устюгов А.А.

ФГБУН «Институт физиологически активных веществ» РАН

Даты поступления:

08.11.2019

Даты принятия в печать:

10.04.2020

Список литературы:

Van Den Bosch L. Genetic rodent models of amyotrophic lateral sclerosis. J Biomed Biotechnol. 2011;348765. https://doi.org/10.1155/2011/348765
Robberecht W, Sapp P, Viaene MK, Rosen D, McKenna-Yasek D, Haines J, Horvitz R, Theys P, Brown R Jr. Cu/Zn superoxide dismutase activity in familial and sporadic amyotrophic lateral sclerosis. J Neurochem. 1994;62(1):384-387. https://doi.org/10.1046/j.1471-4159.1994.62010384.x
Koppers M, van Blitterswijk MM, Vlam L, Rowicka PA, van Vught PW, Groen EJ, Spliet WG, Engelen-Lee J, Schelhaas HJ, de Visser M, van der Kooi AJ, van der Pol WL, Pasterkamp RJ, Veldink JH, van den Berg LH. VCP mutations in familial and sporadic amyotrophic lateral sclerosis. Neurobiol Aging. 2012;33:837. https://doi.org/10.1016/j.neurobiolaging.2011.10.006
Maruyama H, Morino H, Ito H, Izumi Y, Kato H, Watanabe Y, Kinoshita Y, Kamada M, Nodera H, Suzuki H, Komure O, Matsuura S, Kobatake K, Morimoto N, Abe K, Suzuki N, Aoki M, Kawata A, Hirai T, Kato T, Ogasawara K, Hirano A, Takumi T, Kusaka H, Hagiwara K, Kaji R, Kawakami H. Mutations of optineurin in amyotrophic lateral sclerosis. Nature. 2010;465:223-226. https://doi.org/10.1038/nature08971
Daoud H, Suhail H, Szuto A, Camu W, Salachas F, Meininger V, Bouchard JP, Dupré N, Dion PA, Rouleau GA. UBQLN2 mutations are rare in French and French-Canadian amyotrophic lateral sclerosis. Neurobiol Aging. 2012;33(2):2230-2233. https://doi.org/10.1016/j.neurobiolaging.2012.03.015
DeJesus-Hernandez M, Mackenzie IR, Boeve BF, Boxer AL, Baker M, Rutherford NJ, Nicholson AM, Finch NA, Flynn H, Adamson J, Kouri N, Wojtas A, Sengdy P, Hsiung GY, Karydas A, Seeley WW, Josephs KA, Coppola G, Geschwind DH, Wszolek ZK, Feldman H, Knopman DS, Petersen RC, Miller BL, Dickson DW, Boylan KB, Graff-Radford NR, Rademakers R. Expanded GGGGCC hexanucleotide repeat in noncoding region of C9ORF72 causes chromosome 9p-linked FTD and ALS. Neuron. 2011;72:245-256. https://doi.org/10.1016/j.neuron.2011.09.011
Mackenzie IR, Bigio EH, Ince PG, Geser F, Neumann M, Cairns NJ, Kwong LK, Forman MS, Ravits J, Stewart H, Eisen A, McClusky L, Kretzschmar HA, Monoranu CM, Highley JR, Kirby J, Siddique T, Shaw PJ, Lee VM, Trojanowski JQ. Pathological TDP-43 distinguishes sporadic amyotrophic lateral sclerosis from amyotrophic lateral sclerosis with SOD1 mutations. Ann Neurol. 2007;61:427-434. https://doi.org/10.1002/ana.21147
Kwiatkowski TJ, Bosco DA, Leclerc AL, Tamrazian E, Vanderburg CR. Mutations in the FUS/TLS gene on chromosome 16 cause familial amyotrophic lateral sclerosis. Science. 2009;323:1205-1208. https://doi.org/10.1126/science.1166066
Deng HX, Zhai H, Bigio EH, Yan J, Fecto F, Ajroud K, Mishra M, Ajroud-Driss S, Heller S, Sufit R, Siddique N, Mugnaini E, Siddique T. FUS-immunoreactive inclusions are a common feature in sporadic and nonSOD1 familial amyotrophic lateral sclerosis. Ann Neurol. 2010;67:739-748. https://doi.org/10.1002/ana.22051
Daoud H, Dobrzeniecka S, Camu W, Meininger V, Dupré N, Dion PA, Rouleau GA. Mutation analysis of PFN1 in familial amyotrophic lateral sclerosis patients. Neurobiol Aging. 2013;34(4):1311.e1-e2. https://doi.org/10.1016/j.neurobiolaging.2012.09.001
Münch C, Sedlmeier R, Meyer T, Homberg V, Sperfeld AD, Kurt A, Prudlo J, Peraus G, Hanemann CO, Stumm G, Ludolph AC. Point mutations of the p150 subunit of dynactin (DCTN1) gene in ALS. Neurology. 2004;63(4):724-726. https://doi.org/10.1212/01.WNL.0000134608.83927.B1
Rademakers R, van Blitterswijk M. Excess of rare damaging TUBA4A variants suggests cytoskeletal defects in ALS. Neuron. 2014;84(2):241-243. https://doi.org/10.1016/j.neuron.2014.10.002
Ghasemi M, Brown RH. Genetics of amyotrophic lateral sclerosis. Cold Spring Harb Perspect Med. 2017;7:a024125. https://doi.org/10.1101/cshperspect.a024125
Van Damme P, Dewil M, Robberecht W, Van Den Bosch L. Excitotoxicity and Amyotrophic Lateral Sclerosis. Neurodegener Dis. 2005;2(3-4):147-159. https://doi.org/10.1159/000089620
Shi P, Gal J, Kwinter DM, Liu X, Zhu H. Mitochondrial dysfunction in amyotrophic lateral sclerosis. Biochim Biophys Acta. 2010;1802(1):45-51. https://doi.org/10.1016/j.bbadis.2009.08.012
Chitnis T, Weiner HL. CNS inflammation and neurodegeneration. J Clin Invest. 2017;127(10):3577-3587. https://doi.org/10.1172/JCI90609
Miller RG, Mitchell JD, Moore DH. Riluzole for amyotrophic lateral sclerosis (ALS)/motor neuron disease (MND). Cochrane Database Syst Rev. 2012;14(3):CD001447. https://doi.org/10.1002/14651858.CD001447.pub3
Bhandari R, Kuhad A, Kuhad A. Edaravone: a new hope for deadly amyotrophic lateral sclerosis. Drugs Today (Barc). 2018;54(6):349-360. https://doi.org/10.1358/dot.2018.54.6.2828189
Peters OM, Ghasemi M, Brown RH Jr. Emerging mechanisms of molecular pathology in ALS. J Clin Invest. 2015;125(5):1767-1779. https://doi.org/10.1172/jci71601
Ripps ME, Huntley GW, Hof PR, Morrison JH, Gordon JW. Transgenic mice expressing an altered murine superoxide dismutase gene provide an animal model of amyotrophic lateral sclerosis. Proc Natl Acad Sci USA. 1995;92(3):689-693. https://doi.org/10.1073/pnas.92.3.689
Bowling AC, Schulz JB, Brown RH Jr, Beal MF. Superoxide dismutase activity, oxidative damage, and mitochondrial energy metabolism in familial and sporadic amyotrophic lateral sclerosis. J Neurochem. 1993;61(6):2322-2325. https://doi.org/10.1111/j.1471-4159.1993.tb07478.x
McCombe PA, Henderson RD. The Role of Immune and Inflammatory Mechanisms in ALS. Curr Mol Med. 2011;11(3):246-254. https://doi.org/10.2174/1566211213754895240
D’Amico E, Factor-Litvak P, Santella RM, Mitsumoto H. Clinical perspective on oxidative stress in sporadic amyotrophic lateral sclerosis. Free Radic Biol Med. 2013;65:509-527. https://doi.org/10.1016/j.freeradbiomed.2013.06.029
Nagase M, Yamamoto Y, Miyazaki Y, Yoshino H. Increased oxidative stress in patients with amyotrophic lateral sclerosis and the effect of edaravone administration. Redox Rep. 2016;21(3):104-112. https://doi.org/10.1179/1351000215Y.0000000026
Boillée S, Yamanaka K, Lobsiger CS, Copeland NG, Jenkins NA, Kassiotis G, Kollias G, Cleveland DW. Onset and progression in inherited ALS determined by motor neurons and microglia. Science. 2006;312(5778):1389-1392. https://doi.org/10.1126/science.1123511
Philips T, Rothstein JD. Glial cells in amyotrophic lateral sclerosis. Exp Neurol. 2014;262 Pt B:111-120. https://doi.org/10.1016/j.expneurol.2014.05.015
Ozdinler PH, Benn S, Yamamoto TH, Güzel M, Brown RH Jr, Macklis JD. Corticospinal motor neurons and related subcerebral projection neurons undergo early and specific neurodegeneration in hSOD1G9³A transgenic ALS mice. J Neurosci. 2011;31(11):4166-4177. https://doi.org/10.1523/JNEUROSCI.4184-10.2011
Hatzipetros T, Bogdanik LP, Tassinari VR, Kidd JD, Moreno AJ, Davis C, Osborne M, Austin A, Vieira FG, Lutz C, Perrin S. C57BL/6J congenic Prp-TDP43A315T mice develop progressive neurodegeneration in the myenteric plexus of the colon without exhibiting key features of ALS. Brain Res. 2014;1584:59-72. https://doi.org/10.1016/j.brainres.2013.10.013
Joyce PI, Fratta P, Fisher EM, Acevedo-Arozena A. SOD1 and TDP-43 animal models of amyotrophic lateral sclerosis: recent advances in understanding disease toward the development of clinical treatments. Mamm Genome. 2011;22(7-8):420-448. https://doi.org/10.1007/s00335-011-9339-1
Kang SH, Li Y, Fukaya M, Lorenzini I, Cleveland DW, Ostrow LW, Rothstein JD, Bergles DE. Degeneration and impaired regeneration of gray matter oligodendrocytes in amyotrophic lateral sclerosis. Nat Neurosci. 2013;16(5):571-579. https://doi.org/10.1038/nn.3357
Kriz J, Nguyen MD, Julien JP. Minocycline slows disease progression in a mouse model ofamyotrophic lateral sclerosis. Neurobiology of disease. 2002;10:268-278. https://doi.org/10.1006/nbdi.2002.0487
Van Den Bosch L, Tilkin P, Lemmens G, Robberecht W. Minocycline delays disease onset and mortality in a transgenic model of ALS. Neuroreport. 2002;13:1067-1070. https://doi.org/10.1097/00001756-200206120-00018
Philips T, Bento-Abreu A, Nonneman A, Haeck W, Staats K, Geelen V, Hersmus N, Küsters B, Van Den Bosch L, Van Damme P, Richardson WD, Robberecht W. Oligodendrocyte dysfunction in the pathogenesis of amyotrophic lateral sclerosis. Brain. 2013;136(Pt 2):471-482. https://doi.org/10.1093/brain/aws339
Kwong LK, Neumann M, Sampathu DM, Lee VM, Trojanowski JQ. TDP-43 proteinopathy: the neuropathology underlying major forms of sporadic and familial frontotemporal lobar degeneration and motor neuron disease. Acta Neuropathol. 2007;114(1):63-70. https://doi.org/10.1007/s00401-007-0226-5
Rutherford NJ, Zhang YJ, Baker M, Gass JM, Finch NA, Xu YF, Stewart H, Kelley BJ, Kuntz K, Crook RJ, Sreedharan J, Vance C, Sorenson E, Lippa C, Bigio EH, Geschwind DH, Knopman DS, Mitsumoto H, Petersen RC, Cashman NR, Hutton M, Shaw CE, Boylan KB, Boeve B, Graff-Radford NR, Wszolek ZK, Caselli RJ, Dickson DW, Mackenzie IR, Petrucelli L, Rademakers R. Novel mutations in TARDBP (TDP-43) in patients with familial amyotrophic lateral sclerosis. PLoS Genet. 2008;4(9):e1000193. https://doi.org/10.1371/journal.pgen.1000193
Sreedharan J, Blair IP, Tripathi VB, Hu X, Vance C, Rogelj B, Ackerley S, Durnall JC, Williams KL, Buratti E, Baralle F, de Belleroche J, Mitchell JD, Leigh PN, Al-Chalabi A, Miller CC, Nicholson G, Shaw CE. TDP-43 mutations in familial and sporadic amyotrophic lateral sclerosis. Science. 2008;319(5870):1668-1672. https://doi.org/10.1126/science.1154584
Lagier-Tourenne C, Polymenidou M, Hutt KR, Vu AQ, Baughn M, Huelga SC, Clutario KM, Ling SC, Liang TY, Mazur C, Wancewicz E, Kim AS, Watt A, Freier S, Hicks GG, Donohue JP, Shiue L, Bennett CF, Ravits J, Cleveland DW, Yeo GW. Divergent roles of ALS-linked proteins FUS/TLS and TDP-43 intersect in processing long pre-mRNAs. Nat Neurosci. 2012;15(11):1488-1497. https://doi.org/10.1038/nn.3230
Polymenidou M, Lagier-Tourenne C, Hutt KR, Bennett CF, Cleveland DW, Yeo GW. Misregulated RNA processing in amyotrophic lateral sclerosis. Brain Res. 2012;1462:3-15. https://doi.org/10.1016/j.brainres.2012.02.059
Sun Z, Diaz Z, Fang X, Hart MP, Chesi A, Shorter J, Gitler AD. Molecular determinants and genetic modifiers of aggregation and toxicity for the ALS disease protein FUS/TLS. PLoS Biol. 2011;9(4):e1000614. https://doi.org/10.1371/journal.pbio.1000614
Thompson VF, Victor RA, Morera AA, Moinpour M, Liu MN, Kisiel CC, Pickrel K, Springhower CE, Schwartz J. Transcription-dependent formation of nuclear granules containing FUS and RNA Pol II. Biochemistry. 2018;57(51):7021-7032. https://doi.org/10.1021/acs.biochem.8b01097
De Santis R, Santini L, Colantoni A, Peruzzi G, de Turris V, Alfano V, Bozzoni I, Rosa A. FUS Mutant Human Motoneurons Display Altered Transcriptome and microRNA Pathways with Implications for ALS Pathogenesis. Stem Cell Rep. 2017;9:1450-1462. https://doi.org/10.1016/j.stemcr.2017.09.004
Alexander EJ, Ghanbari Niaki A, Zhang T, Sarkar J, Liu Y, Nirujogi RS, Pandey A, Myong S, Wang J. Ubiquilin 2 modulates ALS/FTD-linked FUS-RNA complex dynamics and stress granule formation. Proc Natl Acad Sci USA. 2018;115(49):11485-11494. https://doi.org/10.1073/pnas.1811997115
Wang H, Guo W, Mitra J, Hegde PM, Vandoorne T, Eckelmann BJ, Mitra S, Tomkinson AE, Van Den Bosch L, Hegde ML. Mutant FUS causes DNA ligation defects to inhibit oxidative damage repair in Amyotrophic Lateral Sclerosis. Nat Commun. 2018;9(1):3683. https://doi.org/10.1038/s41467-018-06111-6
Delva L, Gallais I, Guillouf C, Denis N, Orvain C, Moreau-Gachelin F. Multiple functional domains of the oncoproteins Spi-1/PU.1 and TLS are involved in their opposite splicing effects in erythroleukemic cells. Oncogene. 2004;23(25):4389-4399. https://doi.org/10.1038/sj.onc.1207578
Uranishi H, Tetsuka T, Yamashita M, Asamitsu K, Shimizu M, Itoh M, Okamoto T. Involvement of the pro-oncoprotein TLS (translocated in liposarcoma) in nuclear factor-kappa B p65-mediated transcription as a coactivator. J Biol Chem. 2001;276(16):13395-13401. https://doi.org/10.1074/jbc.m011176200
Immanuel D, Zinszner H, Ron D. Association of SARFH (sarcoma-associated RNA-binding fly homolog) with regions of chromatin transcribed by RNA polymerase II. Mol Cell Biol. 1995;15(8):4562-4571. https://doi.org/10.1128/mcb.15.8.4562
Shelkovnikova TA, Peters OM, Deykin AV, Connor-Robson N, Robinson H, Ustyugov AA, Bachurin SO, Ermolkevich TG, Goldman IL, Sadchikova ER, Kovrazhkina EA, Skvortsova VI, Ling SC, Da Cruz S, Parone PA, Buchman VL, Ninkina NN. Fused in sarcoma (FUS) protein lacking nuclear localization signal (NLS) and major RNA binding motifs triggers proteinopathy and severe motor phenotype in transgenic mice. J Biol Chem. 2013;288(35):25266-25274. https://doi.org/10.1074/jbc.M113.492017
Robinson HK, Deykin AV, Bronovitsky EV, Ovchinnikov RK, Ustyugov AA, Shelkovnikova TA, Kukharsky MS, Ermolkevich TG, Goldman IL, Sadchikova ER, Kovrazhkina EA, Bachurin SO, Buchman VL, Ninkina NN. Early lethality and neuronal proteinopathy in mice expressing cytoplasm-targeted FUS that lacks the RNA recognition motif. Amyotroph Lateral Scler Frontotemporal Degener. 2015;16(5-6):402-409. https://doi.org/10.3109/21678421.2015.1040994
Deng HX, Chen W, Hong ST, Boycott KM, Gorrie GH, Siddique N, Yang Y, Fecto F, Shi Y, Zhai H, Jiang H, Hirano M, Rampersaud E, Jansen GH, Donkervoort S, Bigio EH, Brooks BR, Ajroud K, Sufit RL, Haines JL, Mugnaini E, Pericak-Vance MA, Siddique T. Mutations in UBQLN2 cause dominant X-linked juvenile and adult-onset ALS and ALS/dementia. Nature. 2011;477(7363):211-215. https://doi.org/10.1038/nature10353
Watts GD, Wymer J, Kovach MJ, Mehta SG, Mumm S, Darvish D, Pestronk A, Whyte MP, Kimonis VE. Inclusion body myopathy associated with Paget disease of bone and frontotemporal dementia is caused by mutant valosin-containing protein. Nat Genet. 2004;36(4):377-381. https://doi.org/10.1038/ng1332
Weihl CC, Miller SE, Hanson PI, Pestronk A. Transgenic expression of inclusion body myopathy associated mutant p97/VCP causes weakness and ubiquitinated protein inclusions in mice. Hum Mol Genet. 2007;16(8):919-928. https://doi.org/10.1093/hmg/ddm037
Nalbandian A, Nguyen C, Katheria V, Llewellyn KJ, Badadani M, Caiozzo V, Kimonis VE. Exercise training reverses skeletal muscle atrophy in an experimental model of VCP disease. PLoS One. 2013;8(10):e76187. https://doi.org/10.1371/journal.pone.0076187
Chen X, Yazdani S, Piehl F, Magnusson PKE, Fang F. Polygenic link between blood lipids and amyotrophic lateral sclerosis. Neurobiol Aging. 2018;67:202.e1-202.e6. https://doi.org/10.1016/j.neurobiolaging.2018.03.022
Dupuis L, Corcia P, Fergani A, Gonzalez De Aguilar JL, Bonnefont-Rousselot D, Bittar R, Seilhean D, Hauw JJ, Lacomblez L, Loeffler JP, Meininger V. Dyslipidemia is a protective factor in amyotrophic lateral sclerosis. Neurology. 2008;70(13):1004-1009. https://doi.org/10.1212/01.wnl.0000285080.70324.27
Huang R, Guo X, Chen X, Zheng Z, Wei Q, Cao B, Zeng Y, Shang H. The serum lipid profiles of amyotrophic lateral sclerosis patients: A study from south-west China and a meta-analysis. Amyotroph Lateral Scler Frontotemporal Degener. 2015;16(5-6):359-365. https://doi.org/10.3109/21678421.2015.1047454
Rafiq MK, Lee E, Bradburn M, McDermott CJ, Shaw PJ. Effect of lipid profile on prognosis in the patients with amyotrophic lateral sclerosis: Insights from the olesoxime clinical trial. Amyotroph Lateral Scler Frontotemporal Degener. 2015;16(7-8):478-484. https://doi.org/10.3109/21678421.2015.1062517
Chiò A, Calvo A, Ilardi A, Cavallo E, Moglia C, Mutani R, Palmo A, Galletti R, Marinou K, Papetti L, Mora G. Lower serum lipid levels are related to respiratory impairment in patients with ALS. Neurology. 2009;73(20):1681-1685. https://doi.org/10.1212/wnl.0b013e3181c1df1e
Henriques A, Blasco H, Fleury MC, Corcia P, Echaniz-Laguna A, Robelin L, Rudolf G, Lequeu T, Bergaentzle M, Gachet C, Pradat PF, Marchioni E, Andres CR, Tranchant C, Gonzalez De Aguilar JL, Loeffler JP. Blood Cell Palmitoleate-Palmitate Ratio Is an Independed Prognistic Factor for Amyotrophic Lateral Sclerosis. PLoS One. 2015;10(7):e0131512. https://doi.org/10.1371/journal.pone.0131512
Боровик Т.Э., Грибакин С.Г., Скворцова В.А., Семенова Н.Н., Степанова Т.Н., Звонкова Н.Г. Длинноцепочечные полиненасыщенные жирные кислоты и их роль в детском питании. Обзор литературы. Вопросы современной педиатрии. 2012;11(4):21-28. https://doi.org/10.15690/vsp.v11i4.355
Fitzgerald KC, O’Reilly ÉJ, Falcone GJ, McCullough ML, Park Y, Kolonel LN, Ascherio A. Dietary ω-3 polyunsaturated fatty acid intake and risk for amyotrophic lateral sclerosis. JAMA Neurol. 2014;71(9):1102-1110. https://doi.org/10.1001/jamaneurol.2014.1214
Cacabelos D, Ayala V, Granado-Serrano AB, Jové M, Torres P, Boada J, Cabré R, Ramírez-Núñez O, Gonzalo H, Soler-Cantero A, Serrano JC, Bellmunt MJ, Romero MP, Motilva MJ, Nonaka T, Hasegawa M, Ferrer I, Pamplona R, Portero-Otín M. Interplay between TDP-43 and docosahexaenoic acid-related processes in amyotrophic lateral sclerosis. Neurobiol Dis. 2016;88:148-160. https://doi.org/10.1016/j.nbd.2016.01.007
Liu G, Fiala M, Mizwicki MT, Sayre J, Magpantay L, Siani A, Mahanian M, Chattopadhyay M, La Cava A, Wiedau-Pazos M. Neuronal phagocytosis by inflammatory macrophages in ALS spinal cord: inhibition of inflammation by resolvin D1. Am J Neurodegener Dis. 2012;1(1):60-74. PMID: 22787561.
Iłzecka J. Prostaglandin E2 is increased in amyotrophic lateral sclerosis patients. Acta Neurol Scand. 2003;108(2):125-129. https://doi.org/10.1034/j.1600-0404.2003.00102.x
Miyagishi H, Kosuge Y, Takano A, Endo M, Nango H, Yamagata-Murayama S, Hirose D, Kano R, Tanaka Y, Ishige K, Ito Y. Increased Expression of 15-Hydroxyprostaglandin Dehydrogenase in Spinal Astrocytes During Disease Progression in a Model of Amyotrophic Lateral Sclerosis. Cell Mol Neurobiol. 2017;37(3):445-452. https://doi.org/10.1007/s10571-016-0377-9
Yip PK, Pizzasegola C, Gladman S, Biggio ML, Marino M, Jayasinghe M, Ullah F, Dyall SC, Malaspina A, Bendotti C, Michael-Titus A. The omega-3 fatty acid eicosapentaenoic acid accelerates disease progression in a model of amyotrophic lateral sclerosis. PLoS One. 2013;8(4):e61626. https://doi.org/10.1371/journal.pone.0061626
Diaz-Amarilla P, Miquel E, Trostchansky A, Trias E, Ferreira AM, Freeman BA, Cassina P, Barbeito L, Vargas MR, Rubbo H. Electrophilic nitro-fatty acids prevent astrocyte-mediated toxicity to motor neurons in a cell model of familial amyotrophic lateral sclerosis via nuclear factor erythroid 2-related factor activation. Free Radic Biol Med. 2016;95:112-120. https://doi.org/10.1016/j.freeradbiomed.2016.03.013
Rubbo H. Nitro-fatty acids: novel anti-inflammatory lipid mediators. Braz J Med Biol Res. 2013;46(9):728-734. https://doi.org/10.1590/1414-431X20133202
Trostchansky A, Mastrogiovanni M, Miquel E, Rodríguez-Bottero S, Martínez-Palma L, Cassina P, Rubbo H. Profile of Arachidonic Acid-Derived Inflammatory Markers and Its Modulation by Nitro-Oleic Acid in an Inherited Model of Amyotrophic Lateral Scleros. Front Mol Neurosci. 2018;11:131. https://doi.org/10.3389/fnmol.2018.00131
Veldink JH, Kalmijn S, Groeneveld GJ, Wunderink W, Koster A, de Vries JH, van der Luyt J, Wokke JH, Van den Berg LH. Intake of polyunsaturated fatty acids and vitamin E reduces the risk of developing amyotrophic lateral sclerosis. J Neurol Neurosurg Psychiatry. 2007;78(4):367-371. https://doi.org/10.1136/jnnp.2005.083378
Zhao W, Varghese M, Vempati P, Dzhun A, Cheng A, Wang J, Lange D, Bilski A, Faravelli I, Pasinetti GM. Caprylic Triglyceride as a Novel Therapeutic Approach to Effectively Improve the Performance and Attenuate the Symptoms Due to the Motor Neuron Loss in ALS Disease. PLoS One. 2012;7(11):e49191. https://doi.org/10.1371/journal.pone.0049191
Wuolikainen A, Acimovic J, Lövgren-Sandblom A, Parini P, Andersen PM, Björkhem I. Cholesterol, Oxysterol, Triglyceride, and Coenzyme Q Homeostasis in ALS. Evidence against the Hypothesis That Elevated 27-Hydroxycholesterol. Is a Pathogenic Factor PLoS One. 2014;9(11):e113619. https://doi.org/10.1371/journal.pone.0113619
Dorst J, Kühnlein P, Hendrich C, Kassubek J, Sperfeld AD, Ludolph AC Patients with elevated triglyceride and cholesterol serum levels have a prolonged survival in amyotrophic lateral sclerosis. J Neurol. 2011;258(4):613-617. https://doi.org/10.1007/s00415-010-5805-z
Blasco H, Veyrat-Durebex C, Bocca C, Patin F, Vourc’h P, Kouassi Nzoughet J, Lenaers G, Andres CR, Simard G, Corcia P, Reynier P. Lipidomics Reveals Cerebrospinal-Fluid Signatures of ALS. Sci Rep. 2017;7(1):17652. https://doi.org/10.1038/s41598-017-17389-9
Алесенко АВ. Потенциальная роль сфинголипидов в нейропатогенезе болезни Альцгеймера. Биомедицинская химия. 2013;59(1):25-50. https://doi.org/10.18097/pbmc20135901025
Arima H, Omura T, Hayasaka T, Masaki N, Hanada M, Xu D, Banno T, Kobayashi K, Takeuchi H, Kadomatsu K, Matsuyama Y, Setou M. Reductions of docosahexaenoic acid-containing phosphatidylcholine levels in the anterior horn of an ALS mouse model. Neuroscience. 2015;297:127-136. https://doi.org/10.1016/j.neuroscience.2015.03.060
Sutedja NA, van der Schouw YT, Fischer K, Sizoo EM, Huisman MH, Veldink JH, Van den Berg LH. Beneficial vascular risk profile is associated with amyotrophic lateral sclerosis. J Neurol Neurosurg Psychiatry. 2011;82(6):638-642. https://doi.org/10.1136/jnnp.2010.236752
Russell DW, Halford RW, Ramirez DM, Shah R, Kotti T. Cholesterol 24-hydroxylase: an enzyme of cholesterol turnover in the brain. Annu Rev Biochem. 2009;78:1017-1040. https://doi.org/10.1146/annurev.biochem.78.072407.103859
Poirier J, Baccichet A, Dea D, Gauthier S. Cholesterol synthesis and lipoprotein reuptake during synaptic remodelling in hippocampus in adult rats. Neuroscience. 1993;55(1):81-90. https://doi.org/10.1016/0306-4522(93)90456-p
Mukhutdinova KA, Kasimov MR, Giniatullin AR, Zakyrjanova GF, Petrov AM. 24S-hydroxycholesterol suppresses neuromuscular transmission in SOD1 (G93A) mice: A possible role of NO and lipid rafts. Mol Cell Neurosci. 2018;88:308-318. https://doi.org/10.1016/j.mcn.2018.03.006
Vejux A, Namsi T, Nury T, Moreau T, Lizard G. Biomarkers of amyotrophic lateral sclerosis: current status and interest of oxysterols. Front Mol Neurosci. 2018;11:12. https://doi.org/10.3389/fnmol.2018.00012
Diekstra FP, Saris, Christiaan GJ, Rheenen W, Franke L, Ritsert CJ, van Es MA, van Vught PWJ, Blauw HM, Groen EJN, Horvath S, Estrada K, Rivadeneira F, Hofman A, Uitterlinden AG, Robberecht W, Andersen PM, Melki J, Meininger V, Hardiman O, Landers JE, Brown RHJr, Shatunov A, Shaw CE, P. Leigh N, Al-Chalabi A,. Ophoff RA, van den Berg LH Veldink JH. Mapping of Gene Expression Reveals CYP27A1 as a Susceptibility Gene for Sporadic ALS. PLoS One. 2012;7(4):e35333. https://doi.org/10.1371/journal.pone.0035333
Antonini A, Caioli S, Saba L, Vindigni G, Biocca S, Canu N, Zona C. Membrane cholesterol depletion in cortical neurons highlights altered NMDA receptor functionality in a mouse model of amyotrophic lateral sclerosis. Biochim Biophys Acta. 2018;1864(2):509-519. https://doi.org/10.1016/j.bbadis.2017.11.008

Закрыть метаданные